术后第2天C反应蛋白可识别结肠癌切除术后吻合口漏低风险患者
这项两队列多中心诊断准确性研究评估结肠癌切除术后第2天(POD2)C反应蛋白(CRP)<100 mg/L能否排除吻合口漏(AL)。测试队列(n=401)和验证队列(n=213)中AL发生率分别为4.0%和4.7%,POD2 CRP<100 mg/L者AL仅1.3%和1.0%,阴性预测值达98.8%和99.0%。结论支持在加速康复外科(ERAS)路径中以POD2 CRP联合选择性POD3复评支持安全早期出院。
要点
- POD2 CRP<100 mg/L者AL风险约1%,阴性预测值98.8%–99.0%。
- POD2 CRP≥100 mg/L者AL发生率8.1%和7.8%,需POD3复评。
- 两步策略可使近90%患者在POD2或3出院,AL风险近1%。
核心结论
- POD2 CRP<100 mg/L联合选择性POD3复评,可为ERAS路径下结肠癌切除术后安全早期出院提供简单算法。
研究设计与样本
- 两队列多中心诊断准确性研究,纳入择期结肠癌切除一期吻合患者,测试队列n=401,验证队列n=213。
- AL定义为Clavien-Dindo分级≥3级。
主要发现
- 测试队列和验证队列AL发生率分别为4.0%和4.7%。
- POD2 CRP<100 mg/L者分别占60%(240例)和46%(97例),AL仅1.3%和1.0%,阴性预测值98.8%和99.0%。
- POD2 CRP≥100 mg/L者AL发生率分别为8.1%和7.8%。
- 合并队列中POD3/POD2比值<1进一步分层高风险患者,微创手术和开放手术阴性预测值分别为98.9%和97.9%。
- 两步策略下近90%患者可在POD2或3出院,AL风险近1%。
关键数值与推荐
- POD2 CRP<100 mg/L用于排除AL,阴性预测值98.8%和99.0%。
- POD2 CRP≥100 mg/L者评估POD3/POD2比值<1,微创和开放手术阴性预测值98.9%和97.9%。
临床怎么用
- ERAS路径下结肠癌切除术后可检测POD2 CRP,<100 mg/L者AL风险低,可考虑早期出院。
- POD2 CRP≥100 mg/L者应结合POD3/POD2比值<1进一步评估,以支持安全出院决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether C-reactive protein (CRP) <100 mg/L on postoperative day (POD) 2 excludes anastomotic leakage (AL) after colon cancer resection. SUMMARY BACKGROUND DATA: CRP <100 mg/L on POD3 is widely used to exclude AL, but enhanced recovery after surgery (ERAS) increasingly discharges patients before POD3, highlighting the need for an earlier biochemical criterion. METHODS: This two-cohort multicenter diagnostic accuracy study included patients undergoing elective colon cancer resection with primary anastomosis. AL was defined as Clavien-Dindo grade ≥3. POD2 CRP <100 mg/L was evaluated for excluding AL. In patients with POD2 CRP ≥100 mg/L, POD3 dynamics were evaluated using a POD3/POD2 ratio <1. RESULTS: AL occurred in 4.0% and 4.7% of patients in test (n=401) and validation (n=213) cohorts. POD2 CRP <100 mg/L was present in 240 (60%) and 97 (46%) patients, with AL in only 1.3% and 1.0%, yielding negative predictive values (NPVs) of 98.8% and 99.0%. In contrast, AL occurred in 8.1% and 7.8% of patients with POD2 CRP ≥100 mg/L. In the combined cohort, a POD3/POD2 ratio <1 further stratified risk among these higher-risk patients, with NPVs of 98.9% and 97.9% for minimally invasive and open surgery, respectively, and using this two-step strategy, nearly 90% of patients could be discharged by POD2 or 3 with AL risk near 1%. CONCLUSIONS: POD2 CRP <100 mg/L, supplemented by selective POD3 reassessment, provides a simple algorithm to support safe early discharge after colon cancer resection within ERAS pathways.
引用
- Sinimäki S, Andersen CL, Nors J, et al. Postoperative Day 2 C-reactive Protein Identifies Patients at Low Risk of Anastomotic Leakage After Colon Cancer Resection. Ann Surg. 2026. PMID: 42850694. doi:10.1097/SLA.0000000000007234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。